Čes. slov. farm. 2011, 60(1):17-24
Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection
- 1 Univerzita Karlova v Praze, Katedra organické a jaderné chemie, Přírodovědecká fakulta
- 2 Univerzita Karlova v Praze, Farmakologický ústav 1. lékařské fakulty
The study aimed to establish and validate an analytical method for the determination of nabumetone and 6-methoxy-2-naphthylacetic acid (6-MNA) in human plasma after a single therapeutic dose of the drug. Two methods based on HPLC with UV and MS detection were compared. Optimal results in sample preparation were achieved using solid phase extraction. The recovery reached approximately 84% and 86-90% for nabumetone and 6-MNA, respectively. A reverse C18 column was used for HPLC separation of the analytes. The limit of UV detection was 50 nM and 0.1 μM for 6-MNA and nabumetone, respectively. The limit of MS detection was 1 μM and 0.5 μM for 6-MNA and nabumetone, respectively. Precision ranged between 4.2-14.4% and 4.6-8.5% using UV and MS detection for nabumetone, respectively. The respective values for 6-MNA were 2.4-12.5% and 2.1-9.4%. Accuracy ranged between 93.4-109.6% in UV detection and 86.2-107.9% using UV and MS detection for nabumetone, respectively. The respective values for 6-MNA were 87.8-107.4% and 86.3-106.4%. The method was subsequently applied to determine the pharmacokinetic parameters of nabumetone and 6-MNA in a group of 24 healthy volunteers.
Keywords: nabumetone; pharmacokinetics; 6-methoxy-2-naphthylacetic acid; HPLC; LC, MS
Grants and funding:
Práce vznikla za podpory grantu GA UK 52707.
Received: November 26, 2010; Accepted: December 20, 2010; Published: January 1, 2011 Show citation
References
- Boyle, E. A., Freeman, P. C., Mangan, F. R., Thomson, M. J.: Nabumetone (BRL 14777, 4-[6-methoxy-2-naphthyl]-butan-2-one): a new anti-infla-mmatory agent. J Pharm Pharmacol. 1982; 34, 562-569.
Go to original source...
Go to PubMed...
- Battisti, W. P., Katz, N. P., Weaver, A. L., Matsumoto, A. K., Kivitz, A. J., Polis, A. B., Geba, G. P.: Pain management in osteoarthritis: a focus on onset of efficacy - a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. J Pain. 2004; 5, 511-520.
Go to original source...
Go to PubMed...
- Hedner, T., Samulesson, O., Wahrborg, P., Wadenvik, H., Ung K. A., Ekbom, A.: Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs. 2004; 64, 2315-2343; discussion 2344-2315.
Go to original source...
Go to PubMed...
- Kobylinska, K., Barlinska, M., Kobylinska, M.: Analysis of nabumetone in human plasma by HPLC. Application to single dose pharmacokinetic studies. J Pharm Biomed Anal. 2003; 32, 323-328.
Go to original source...
Go to PubMed...
- Starek, M., Krzek, J.: A review of analytical techniques for determination of oxicams, nimesulide and nabumetone. Talanta. 2009; 77, 925-942.
Go to original source...
Go to PubMed...
- Kendall, M. J., Chellingsworth, M. C., Jubb, R., Thawley, A. R., Undre, N. A., Kill, D. C.: A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients. Eur J Clin Pharmacol. 1989; 36, 299-305.
Go to original source...
Go to PubMed...
- Davies, N. M.: Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet. 1997; 33, 404-416.
Go to original source...
Go to PubMed...
- Patel, B. N., Sharma, N., Sanyal, M., Prasad, A., Shrivastav, P. S.: High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. Biomed Chromatogr. 2008; 22, 1213-1224.
Go to original source...
Go to PubMed...
- Srinivas N. R.: Applicability of LC/MS/MS assay for 6-methoxy-2-napthylacetic acid to support the bioequivalence study of nabumetone-comments on the research work of Patel et al. (2008). Biomed Chromatogr. 2009; 23, 674-675.
Go to original source...
Go to PubMed...
- Food and Drug Administration: FDA Guidance for Industry: Bioanalytical Method Validation. 2001; http://www.fda.gov/cder/quidance (15. 11. 2010).